Psychedelic Therapeutics Market Size is valued at USD 2.2 Billion in 2024 and is predicted to reach USD 9.6 Billion by the year 2034 at a 15.6 % CAGR during the forecast period for 2025-2034.
Psychedelic medicines are also referred to as hallucinogenic. Psychedelic medicines are a group of substances, including chemicals, such as LSD, and plants used to treat multiple mental disorders, including resistant depression, opiate addiction, and panic disorder, among others. This medicine changes and enhances sensory perceptions, thought processes, and energy levels and facilitates favorable experiences.
The Global psychedelic therapeutics market is proliferating owing to the increasing incidence of depression cases across the world. Additionally, changed lifestyles and quality of living are supporting the growth of psychedelic medicine market. In addition, the market is anticipated to expand lucratively as a result of the growing need for medicines to treat psychological drug dependency. On the other hand, a greater acceptance of non-therapeutic treatments over allopathic therapies and tight rules implemented by various governments to commercialize psychedelic medications may inhibit the market growth.
In 2023, North America led the market. Major determinants, such as the increase in the frequency of depression and other mental diseases and the rapid advancement of research, are driving the market growth. The population's increased awareness of anxiety and mental health is anticipated to stimulate regional growth further. The Asia-Pacific region is anticipated to see a considerable growth rate over the projected period as a result of the growing awareness of mental diseases and the expansion of healthcare infrastructure.
The global psychedelic therapeutics market is segmented on the basis of Origin of Psychedelic Substance, Type of Psychedelic Substance, Target Therapeutic Area and region. Based on the Origin of Psychedelic Substance, the market is divided into Synthetic Substances and Natural Substances. On the basis of Type of Psychedelic Substance, the market is divided in to GHB, Ketamine, MDMA and Psilocybin.
On the basis of Target Therapeutic Area, the market is divided into Depression and Anxiety Disorders, Pain Disorders, Sleep-Related Disorders and Trauma. Based on region, the market is studied across North America, Asia-Pacific, Europe, and LAMEA. Among that Europe held the largest share of the market, followed by America and Asia Pacific. On the other hand, North America is expected to dominate the market during the analysis of forecast period.
| Report Attribute | Specifications |
| Market Size Value In 2024 | USD 2.2 Billion |
| Revenue Forecast In 2034 | USD 9.6 Billion |
| Growth Rate CAGR | CAGR of 15.6 % from 2025 to 2034 |
| Quantitative Units | Representation of revenue in US$ Billion and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report Coverage | The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
| Segments Covered | Type of Psychedelic Substance, Origin of Psychedelic Substance, Target Therapeutic Area |
| Regional Scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country Scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
| Competitive Landscape | Celon Pharma S.A., MAPS Public Benefit, MindMed, Janssen Pharmaceuticals, iX Biopharma Ltd, Jazz Pharmaceutical, Avadel, Pharmaceuticals plc, NeuroRx, Inc., Douglas Pharmaceuticals Limited, The Emmes, Company, LLC, CaaMTech, COMPASS Pathways plc, Eleusis Benefit Corporation, AWAKN Life Sciences Inc, Psilera Bioscience, Braxia Scientific Corp., Mindset Pharma, BetterLife Pharma, Cybin, CB Therapeutics, Numinus Wellness, Mydecine Innovations Group, Optimi Health, PharmaTher, Field Trip Health, ATAI Life Sciences, GH Research, Seelos Therapeutics, Small Pharma, Bright Minds Biosciences, Incannex Health, PsyBio Therapeutics, Universal Ibogaine, Levitee Labs, Mind Cure Health, Novamind, Clearmind Medicine, MYND Life Science, Wesana Health, Psyched Wellness, HAVN Life Sciences, Tryp Therapeutics, Psyence Group, Silo Pharma, Core One Labs, M2Bio Sciences, Neonmind Biosciences, Delic Corp, Nova Mentis Life Science, Beckley Psytech, Delix Therapeutics, Diamond Therapeutics, Tactogen, Psygen Labs Inc., Bexson Biomedical, Eleusis Biotech, Psilera Biosceince, Octarine Bio, Heading Health, MAPS Public Benefit Corporation (PBC), Aphrodite Health, Terran Biosciences, Mycrodose Therapeutics, Reset Pharma, Clerkenwell Health, Alvarius Pharmaceuticals, Ceruvia Lifesciences, and Other Prominent Player. |
| Customization Scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing And Available Payment Methods | Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Psychedelic Therapeutics Market Snapshot
Chapter 4. Global Psychedelic Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Origin of Substance Estimates & Trend Analysis
5.1. by Origin of Substance & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Origin of Substance:
5.2.1. Natural
5.2.2. Synthetic
Chapter 6. Market Segmentation 2: by Type of Psychedelic Substance Estimates & Trend Analysis
6.1. by Type of Psychedelic Substance & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type of Psychedelic Substance:
6.2.1. Gamma-hydroxybutyrate
6.2.2. Ketamine
6.2.3. MDMA
6.2.4. Psilocybin
Chapter 7. Market Segmentation 3: by Target Disease Indications Estimates & Trend Analysis
7.1. by Target Disease Indications & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Target Disease Indications:
7.2.1. Depression and Anxiety Disorders
7.2.2. Pain Disorders
7.2.3. Sleep Related Disorders
7.2.4. Trauma
Chapter 8. Market Segmentation 4: by Route of Administration Estimates & Trend Analysis
8.1. by Route of Administration& Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route of Administration:
8.2.1. Oral
8.2.2. Intravenous
8.2.3. Intranasal
8.2.4. Sublingual
Chapter 9. Psychedelic Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.1.2. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.1.3. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.1.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.1.5. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.2.2. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.2.3. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.2.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.2.5. Europe Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.3.2. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.3.3. Asia-Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.3.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.3.5. Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.4.2. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.4.3. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034 North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.4.4. North America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.4.5. Latin America Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Origin of Substance, 2021-2034
9.5.2. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type of Psychedelic Substance, 2021-2034
9.5.3. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Target Disease Indications, 2021-2034
9.5.4. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
9.5.5. Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Celon Pharma S.A.
9.2.2. MAPS Public Benefit
9.2.3. MindMed
9.2.4. Janssen Pharmaceuticals
9.2.5. iX Biopharma Ltd
9.2.6. Jazz Pharmaceutical
9.2.7. Avadel
9.2.8. Pharmaceuticals plc
9.2.9. NeuroRx, Inc.
9.2.10. Douglas Pharmaceuticals Limited
9.2.11. The Emmes
9.2.12. Company, LLC
9.2.13. CaaMTech
9.2.14. COMPASS Pathways plc
9.2.15. Eleusis Benefit Corporation
9.2.16. AWAKN Life Sciences Inc
9.2.17. Psilera Bioscience
9.2.18. Braxia Scientific Corp.
9.2.19. Mindset Pharma
9.2.20. BetterLife Pharma
9.2.21. Cybin
9.2.22. CB Therapeutics
9.2.23. Numinus Wellness
9.2.24. Mydecine Innovations Group
9.2.25. Optimi Health
9.2.26. PharmaTher
9.2.27. Field Trip Health
9.2.28. ATAI Life Sciences
9.2.29. GH Research
9.2.30. Seelos Therapeutics
9.2.31. Small Pharma
9.2.32. Bright Minds Biosciences
9.2.33. Incannex Health
9.2.34. PsyBio Therapeutics
9.2.35. Universal Ibogaine
9.2.36. Levitee Labs
9.2.37. Mind Cure Health
9.2.38. Novamind
9.2.39. Clearmind Medicine
9.2.40. MYND Life Science
9.2.41. Wesana Health
9.2.42. Psyched Wellness
9.2.43. HAVN Life Sciences
9.2.44. Tryp Therapeutics
9.2.45. Psyence Group
9.2.46. Silo Pharma
9.2.47. Core One Labs
9.2.48. M2Bio Sciences
9.2.49. Neonmind Biosciences
9.2.50. Delic Corp
9.2.51. Nova Mentis Life Science
9.2.52. Beckley Psytech
9.2.53. Delix Therapeutics
9.2.54. Diamond Therapeutics
9.2.55. Tactogen
9.2.56. Psygen Labs Inc.
9.2.57. Bexson Biomedical
9.2.58. Eleusis Biotech
9.2.59. Psilera Biosceince
9.2.60. Octarine Bio
9.2.61. Heading Health
9.2.62. MAPS Public Benefit Corporation (PBC)
9.2.63. Aphrodite Health
9.2.64. Terran Biosciences
9.2.65. Mycrodose Therapeutics
9.2.66. Reset Pharma
9.2.67. Clerkenwell Health
9.2.68. Alvarius Pharmaceuticals
9.2.69. Ceruvia Lifesciences
9.2.70. Other Prominent Players
Psychedelic Therapeutics Market- By Origin of Substance
Psychedelic Therapeutics Market- By Type of Psychedelic Substance
Psychedelic Therapeutics Market- By Target Disease Indications
Psychedelic Therapeutics Market- By Route of Administration
Global Psychedelic Therapeutics Market Revenue (US$ Mn) Based on Region
Europe Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
North America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
Asia Pacific Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
Latin America Psychedelic Therapeutics Market Revenue (US$ Mn) by Country
Middle East & Africa Psychedelic Therapeutics Market Revenue (US$ Mn) by Country